Results 11 to 20 of about 26,025 (223)
Blood Advances, 2017 Venetoclax is a BH3-mimetic small molecule drug that directly and selectively inhibits BCL-2. BCL-2 is highly expressed in many hematologic malignancies and is the predominant prosurvival protein in diseases such as chronic lymphocytic leukemia (CLL), follicular lymphoma, and mantle cell lymphoma.
openaire +3 more sources
On the Stability and Degradation Pathways of Venetoclax under Stress Conditions
Pharmaceutics, 2020 Venetoclax is an orally bioavailable, B-cell lymphoma-2 (BCL-2) selective inhibitor, used for the treatment of various types of blood cancers, such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Nina Žigart +3 more
doaj +1 more source
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. [PDF]
, 2018 The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells and resistance to therapy. Activation of JAK/STAT signaling is thought to be a central component of these microenvironment-induced phenotypes.
Aftab, Blake T +13 more
core +2 more sources
Cell Death and Disease, 2022 Chronic lymphocytic leukemia (CLL) is a hematological neoplasm of CD19-positive mature-appearing B lymphocytes. Despite the clinical success of targeted therapies in CLL, the development of resistance diminishes their therapeutic activity.
Damjan Avsec +6 more
doaj +1 more source
Targeting BCL-2 regulated apoptosis in cancer [PDF]
, 2018 The ability of a cell to undergo mitochondrial apoptosis is governed by pro- and anti-apoptotic members of the BCL-2 protein family. The equilibrium of pro- versus anti-apoptotic BCL-2 proteins ensures appropriate regulation of programmed cell death ...
Campbell, Kirsteen J. +1 more
core +1 more source
Cancer Medicine, 2023 Background Recently, the combination of venetoclax plus a hypomethylating agent (HMA; azacitidine ordecitabine) or low‐dose cytarabine (LDAC) showed promise in Phase III trials in previously untreated AML.
Louise Laloi +29 more
doaj +1 more source
Scientific Reports, 2023 Treatment-related skeletal complications are common in childhood cancer patients and survivors. Venetoclax is a BCL-2 inhibitor that has shown efficacy in hematological malignancies in adults and is being investigated in pediatric cancer clinical trials ...
Lilly Velentza +5 more
doaj +1 more source
Another treatment option for relapsed or refractory chronic lymphocytic leukaemia. [PDF]
, 2017 We hereby report the clinical and biologic features of 33 of 4680 (0.7%) patients with chronic lymphocytic leukemia (CLL), managed at 10 Italian centers, who developed Hodgkin lymphoma (HL), a rare variant of Richter syndrome.
Mauro, Francesca Romana
core +1 more source
Cancer Cell International, 2020 Venetoclax has been approved by the United States Food and Drug Administration since 2016 as a monotherapy for treating patients with relapsed/refractory chronic lymphocytic leukemia having 17p deletion.
XiaoYan Yue, Qingxiao Chen, JingSong He
doaj +1 more source
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Journal of Hematology & Oncology, 2022 Inhibitors of B cell receptor (BCR) signaling such as the Bruton’s tyrosine kinase (BTK) inhibitors are effective therapeutics for chronic lymphocytic leukemia (CLL).
Elizabeth M. Muhowski +10 more
doaj +1 more source